Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.9894
- Book/Share 38.2151
- PB 8.1562
- Debt/Equity 0.5957
- CurrentRatio 0.7761
- ROIC 0.3599
- MktCap 1385478304840.9907
- FreeCF/Share 14.1116
- PFCF 22.0839
- PE 13.3532
- Debt/Assets 0.1976
- DivYield 0.0348
- ROE 0.6695
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
News
Why Novo Nordisk's Q3 Miss Is A Buying Opportunity
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S delivered mixed Q3 '25 results, with modest revenue growth but a 27% drop in net profit due to higher financing costs. NVO's GLP-1 franchise, led by Ozempic and Wegovy, faces moderated growth and supply constraints, yet remains a key revenue driver at 49% of sales. Promising Phase 3 data for oral Wegovy supports its potential as the first oral GLP-1 obesity therapy, with an FDA decision expected by end-2025.
Read More
Novo Nordisk Q3: Why I'm Not Giving Up Yet
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S shares have plunged nearly 70%, yet the company remains a leader in GLP-1 and obesity drugs with strong growth catalysts. Despite fierce competition and a recent reset phase, NVO's Q3 2025 showed net sales up 15% at CER and operating profit up 21% excluding one-offs. Obesity Care, led by Wegovy, saw 41% sales growth at CER, and the upcoming Wegovy pill approval could significantly boost adoption and revenue.
Read More
Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic
Published: November 05, 2025 by: Investopedia
Sentiment: Negative
U.S.-listed shares of Novo Nordisk (NVO) fell after the drugmaker scaled back its outlook, citing disappointing demand for its GLP-1 weight loss and diabetes drugs as competition in the sector increases.
Read More
Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Negative
NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds.
Read More
Novo Nordisk slashes full-year sales forecast amid competition in diabetes and obesity markets
Published: November 05, 2025 by: Proactive Investors
Sentiment: Negative
Novo Nordisk (NYSE:NVO) shares moved lower after the drugmaker posted weaker-than-expected revenue growth for Q3 and adjusted its full-year guidance, citing reduced growth expectations for its diabetes and obesity products amid increased competition and pricing pressure. Novo Nordisk downwardly revised its guidance, now expecting full-year 2025 sales growth of 8% to 11% at constant exchange rates (CER), down from its earlier guidance of 8% to 14%.
Read More
Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera
Published: November 05, 2025 by: CNBC
Sentiment: Positive
Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
Read More
Novo Nordisk CEO Mike Doustdar on $10B Metsera bid, expanding use of obesity drugs
Published: November 05, 2025 by: CNBC Television
Sentiment: Positive
Novo Nordisk CEO Mike Doustdar joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's bid for obesity biotech company Metsera, negotiations with the Trump administration to sell some of its obesity drugs to consumers at a lower rate, expanding the use of obesity drug, and more.
Read More
Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera
Published: November 04, 2025 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) has outbid Pfizer Inc (NYSE:PFE, ETR:PFE) in a heated contest for obesity-focused biotech Metsera (NASDAQ:MTSR), with the Danish drugmaker's revised offer valuing the company at roughly $10 billion, compared with Pfizer's $8.1 billion proposal. Metsera's board on Tuesday declared Novo Nordisk's amended bid “superior,” setting the stage for a potential acquisition that could reshape the obesity treatment landscape.
Read More
Pfizer and Novo Nordisk both raise bids for Metsera
Published: November 04, 2025 by: CNBC Television
Sentiment: Positive
CNBC's David Faber breaks down the latest details about a bidding war between Pfizer and Novo Nordisk for Metsera.
Read More
Lilly and Novo Nordisk near White House deal on obesity drug prices, Endpoints New reports
Published: November 04, 2025 by: Reuters
Sentiment: Positive
Eli Lilly and Novo Nordisk are preparing to announce new drug pricing deals with the White House, including for their blockbuster weight loss drugs, in return for coverage of products under Medicare, Endpoints New reported on Tuesday, citing sources familiar with the matter.
Read More
Metsera said it received a revised acquisition offer from Novo Nordisk that it called superior to Pfizer's bid
Published: November 04, 2025 by: WSJ
Sentiment: Positive
The new offer constitutes a superior company proposal to Pfizer's bid, Metsera said.
Read More
Novo Nordisk submits updated proposal to acquire Metsera, Inc.
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Today, Novo Nordisk confirms that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior
Read More
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up
Published: November 04, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk and Pfizer have revised their bids for Metsera , the obesity drug developer said on Tuesday.
Read More
Novo Nordisk says Metsera bid won't raise antitrust issues
Published: November 03, 2025 by: Reuters
Sentiment: Positive
Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues.
Read More
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
Published: November 03, 2025 by: CNBC
Sentiment: Negative
Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit escalates a heated standoff between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the blockbuster weight loss drug market.
Read More
Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera
Published: November 03, 2025 by: WSJ
Sentiment: Negative
Lawsuit says the proposed merger of the weight-loss drugmakers could kill off a smaller competitor.
Read More
Novo Nordisk changes tack with bold raid on Pfizer obesity deal
Published: October 30, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market under a new CEO and board.
Read More
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
Published: October 30, 2025 by: Benzinga
Sentiment: Negative
On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).
Read More
Invesco EQV International Equity Fund Q3 2025 Performance Update
Published: October 30, 2025 by: Seeking Alpha
Sentiment: Positive
Invesco EQV International Equity Fund's Q3 2025 performance was driven by strong returns from TSM, Legrand, Trip.com, and Shenzhen Inovance. TSM outperformed on robust AI chip demand and favorable margins, while Legrand benefited from data center growth and Trip.com from travel recovery. Key detractors included Shimano, RELX, and London Stock Exchange, impacted by margin pressures, AI disruption concerns, and rising competition.
Read More
Novo Nordisk: Decade-Low Valuation Meets A Billion-Patient Market
Published: October 24, 2025 by: Seeking Alpha
Sentiment: Positive
Initiating coverage on Novo Nordisk (NVO) with a Strong Buy 70% below its all-time high. NVO's competitive pressures and US political pricing risks are mid-term noise. Global obesity and diabetes markets remain vastly underpenetrated. Valuation is at multi-decade lows, with a TTM P/E of 13-14x versus a 20-year average of 23x, and even below the pre semaglutide-boom average of 21x.
Read More
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.
Read More
Novo Nordisk: The fog begins to lift
Published: October 24, 2025 by: Proactive Investors
Sentiment: Positive
It has been a jittery few months for Novo Nordisk (NYSE:NVO) investors, but Berenberg thinks the worst of the uncertainty may be passing. The broker has reiterated its 'buy' rating and DKK 425 price target, arguing that a run of upcoming announcements should bring long-awaited clarity to the debate over pricing, demand and leadership at the Danish drugmaker.
Read More
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?
Published: October 23, 2025 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.
Read More
NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk stock slides as the Novo Nordisk Foundation pushes a sweeping board overhaul, signaling a new era in governance and strategic direction.
Read More
The Ozempic maker shakes up its board. It has been a year of turmoil for Novo Nordisk.
Published: October 21, 2025 by: Market Watch
Sentiment: Negative
Ozempic maker Novo Nordisk is shaking up its board.
Read More
Novo Nordisk in active talks with Trump administration on MFN
Published: October 21, 2025 by: CNBC Television
Sentiment: Positive
Novo Nordisk U.S. President Dave Moore confirms the company is in active discussions with the Trump administration over most favored nation pricing for its popular GLP-1 drugs Ozempic and Wegovy, as it wraps up talks for the IRA Medicare drug price negotiations. It comes as the company is ramping up its U.S. manufacturing capabilities ahead of the anticipated approval of Wegovy in pill form.
Read More
Novo Nordisk board members step down after clash with controlling shareholder
Published: October 21, 2025 by: CNBC
Sentiment: Negative
Novo Nordisk directors and the firm's controlling shareholder failed to reach an agreement on the future composition of the board.
Read More
Novo Nordisk Chair Helge Lund and six other board members to step down
Published: October 21, 2025 by: Reuters
Sentiment: Neutral
Wegovy-maker Novo Nordisk said on Tuesday its Chair Helge Lund and six other board members will step down at an upcoming extraordinary general meeting on November 14.
Read More
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Oct 2025)
Published: October 21, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Ozempic has become a phenomenon, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Read More
Insight: Novo Nordisk fights to keep Medicaid paying for weight-loss drugs
Published: October 21, 2025 by: Reuters
Sentiment: Neutral
Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as some U.S. states struggle with the treatment's costs, according to state documents, company emails and interviews with lawmakers and advocates.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406